- Home
- SNY
SNY
Sanofi ADS
as 02-21-2025 4:00pm EST
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
| Founded: | 1994 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 134.4B | IPO Year: | N/A |
| Target Price: | $60.00 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 4.60 | EPS Growth: | 2.94 |
| 52 Week Low/High: | $45.22 - $58.97 | Next Earning Date: | 01-30-2025 |
| Revenue: | $45,849,466,833 | Revenue Growth: | 7.73% |
| Revenue Growth (this year): | 9.02% | Revenue Growth (next year): | 6.31% |
Latest Sanofi ADS News
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
3 days ago
Sanofi moves closer to selling controlling stake in $17bn-valued Opella
BioPharma Dive
3 days ago
Sanofi reaches consumer health deal; Supernus antidepressant fails study
Pharma Voice
3 days ago
Challenges mount for vaccine makers
GlobeNewswire
3 days ago
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Zacks
4 days ago
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
Pharmaceutical Technology
4 days ago
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
GlobeNewswire
4 days ago
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Zacks
8 days ago
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Compare SNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.